BioAtla (BCAB) Net Margin (2020 - 2026)
BioAtla's (BCAB) quarterly Net Margin came in at 3.57% in Q2 2026, up 100.78% quarter-over-quarter from 459.1% in Q4 2025.
Powered by 
Analysis
BioAtla (BCAB) Net Margin (2020 - 2026) Analysis & Trends
BioAtla (BCAB) has reported Net Margin for 5 consecutive years, with 3.57% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Margin changed N/A year-over-year to 3.57%; the trailing twelve-month figure through Jun 2026 stood at 375.29% (up 18747.0% YoY), and the FY2025 full-year result was 2923.1%, down 228152.0% from the prior year.
- Net Margin improved to 3.57% in Q2 2026 per BCAB's latest filing, from 459.1% in the prior quarter.
- Across five years, Net Margin topped out at 3.57% in Q2 2026 and bottomed at 459.1% in Q4 2025.
- Historically, Net Margin has averaged 183.92% across 3 years, with a median of 96.24% in 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 23.62% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -134.51% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 32.99% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 30.23% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 31.16% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -539.31% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 12.74% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 3.56% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -3.12% |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - | 3.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.57% |
| Dec 31, 2025 | -459.10% |
| Sep 30, 2024 | -96.24% |
| Jun 30, 2021 | -12,152.40% |
| Sep 30, 2020 | -7,754.67% |
| Jun 30, 2020 | -3,274.74% |
| Mar 31, 2020 | -1,802.25% |